Wednesday, November 26, 2025

SUN-DT moves towards the full digitalization of tower CSP plants to improve efficiency and reduce operational costs



The project, in which IMDEA Networks participates, strengthens Europe’s technological leadership in renewable energy



IMDEA Networks Institute





The European project SUN-DT, in which IMDEA Networks participates and which is funded by Horizon Europe, officially launched its activities in October 2025. Formed by a consortium of nine international organizations and coordinated by CENER, the initiative aims to drive the digital transition of tower concentrated solar power (CSP) plants.

These facilities use thousands of mirrors (heliostats) that track the sun and concentrate its light onto a receiver placed at the top of a tower. There, the captured solar energy is converted into high-temperature heat, which is later transformed into electricity. Although tower CSP is becoming the dominant technology worldwide, plant performance still depends on extremely complex field operations, with thousands of heliostats, high-temperature receivers and storage systems that must work in perfect synchrony. This is why digitalization is essential to maximize efficiency, cut costs and accelerate deployment.

“With the rapid growth of new tower plants worldwide, Europe must close this digitalization gap now to maintain its leadership and bring costs below the targets set out in the EU’s Strategic Energy Technology (SET) Plan,” says Joerg Widmer, principal investigator of the project and Research Director at IMDEA Networks.

Widmer adds: “SUN-DT pushes tower concentrated solar power (CSP) technology into a fully digital era. By combining AI-based calibration, predictive maintenance and real-time optimization, we enable plants to operate more efficiently and reliably than ever before. This project strengthens Europe’s technological leadership in renewable energy.”

IMDEA Networks’ role

IMDEA Networks leads the development of the 5G wireless communication layer that will enable the characterization and calibration of heliostats. Its contribution is key to making this tool viable at scale: it provides reliable, high-capacity links across the entire solar field, ensures robust data collection and enables real-time feedback loops.

“We bring deep expertise in wireless sensing and network architecture, as well as testbed-grade infrastructure —such as the NEXTONIC laboratory— which allows us to prototype and validate communication components under realistic conditions,” Widmer explains.

Digital tools

The project will develop four interoperable digital tools —HELIOSTATACC, SUN-DTWIN, D-OPT and PREDOM— that will measurably improve the performance of tower CSP plants. These technologies automate solar-field calibration, generate a digital twin for real-time decision-making, optimize energy dispatch (i.e., how energy is delivered to the grid at any given moment), and enable predictive maintenance.

The objective is to demonstrate:

  • Higher solar-field efficiency and reduced optical losses.
  • Lower operational and maintenance costs and reduced downtime through predictive maintenance.
  • Improved energy dispatch optimization, enabling CSP to participate in grid ancillary services.
  • More competitive renewable generation costs, aligned with the targets of the European SET Plan.

All these tools will be integrated into a unified SUN-DT platform, which will be tested and validated in two experimental facilities and two commercial CSP tower plants: Khi Solar One in South Africa and Cerro Dominador in Chile. These plants are operated by two consortium partners and global leaders in solar energy, COX and ACCIONA respectively, and represent different CSP tower configurations.

“For example, a heliostat calibration and characterization system will automatically detect any misalignment in real time and recommend corrective actions. Instead of scheduling full maintenance rounds, operators will adjust only the mirrors that truly require intervention. This directly improves optical efficiency and saves numerous hours of field work,” Widmer concludes.

 

New U,S, federal loan caps could disrupt the medical field, study finds




Harvard Pilgrim Health Care Institute





Boston, MA — Researchers from the Harvard Pilgrim Health Care Institute have produced the first national estimate of how many medical students would be affected by new federal loan restrictions imposed by the 2025 One Big Beautiful Bill Act (OBBBA). Their findings suggest the reforms are likely to place substantial financial barriers on aspiring physicians, potentially reducing workforce diversity and worsening existing physician shortages.

The study, “Federal Loans Among US Medical Students, 2008-2020,” was published on November 26 in JAMA.

With the U.S. leading the world in medical school costs, students increasingly depend on federal loans to finance their education. This new study cautions that the combination of rising tuition and OBBBA loan restrictions may force medical students toward private lenders with higher interest rates, discourage them from choosing lower-paid but essential specialties such as primary care, or deter them from entering medicine altogether, disproportionately impacting underrepresented students.

“The average cost of attending medical school has greatly increased in just over a decade,” said Tarun Ramesh, research fellow at Harvard Pilgrim Health Care Institute and lead author of the study. “Federal loan restrictions could leave many medical students, especially those from low-income backgrounds, without affordable options to complete their training.” 

Using national data from the National Postsecondary Student Aid Survey, the researchers analyzed federal loan usage, annual borrowing, and total debt among medical student—examining differences by characteristics such as age, sex, income, state of residence, and awareness of loan forgiveness programs. Key findings include:

  • A 38% increase in the average annual cost of medical school attendance between 2008 and 2020.
  • A sharp rise in the use of Graduate PLUS Loans—which allowed medical students to borrow up to their total cost of attendance but will be eliminated under the OBBBA—from 13% in 2008 to 47% in 2020.
  • In 2020, 40% of medical students borrowed more than $50,000 in a single year, and 14% had lifetime federal debt exceeding $200,000—both thresholds that would be capped by the OBBBA.

Low-income and out-of-state students were most likely to exceed both annual and lifetime loan caps. “Graduate PLUS Loans have been a financial lifeline for nearly half of all medical students,” said Hao Yu, Harvard Medical School associate professor of population medicine at the Harvard Pilgrim Health Care Institute, and senior author of the study. “Eliminating this program will create substantial financial barriers for students and most likely reduce diversity in the physician workforce.”

The research team hopes that highlighting the likely real-world impact of the OBBBA’s restrictions on lower-interest federal student loans will prompt policymakers and medical schools to consider the new law’s implications for medical education and physician workforce diversity. They urge exploration of targeted solutions such as loan forgiveness or tuition reduction programs to offset the barriers the new federal restrictions may create.


About the Harvard Pilgrim Health Care Institute’s Department of Population Medicine
The Harvard Pilgrim Health Care Institute's Department of Population Medicine is a unique collaboration between Harvard Pilgrim Health Care and Harvard Medical School. Created in 1992, it is the first appointing medical school department in the United States based in a health plan. The Institute focuses on improving health care delivery and population health through innovative research and education, in partnership with health plans, delivery systems, and public health agencies. Follow us on BlueskyX, and LinkedIn.



JAMA Oncology




About The Study: The monetary consequences of National Cancer Institute recissions is substantial despite the limited relevance of cancer research to ideological controversies. Disrupted grants affected most states and many public and private institutions. Many grant terminations affected research trainees and junior faculty, suggesting that these terminations not only interrupted the continuity of research studies, but also jeopardized career trajectories of early-stage investigators, with potential downstream consequences on the research workforce and innovation pipeline. 


Corresponding Author: To contact the corresponding author, David Hsiehchen, MD, email david.hsieh@utsouthwestern.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamaoncol.2025.4985)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Embed this link to provide your readers free access to the full-text article 

https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2025.4985?guestAccessKey=8e0ca9d5-0f67-4a24-9a97-c26dd8757378&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=112625

 

Trends in injecting methamphetamine and opioids among people who inject drugs in the US




JAMA Network





About The Study: 

During 2012 to 2023, the prevalence of injecting methamphetamine only or both methamphetamine and opioids increased significantly among people who inject drugs entering treatment, including in areas where methamphetamine injection was previously rare (e.g., the Northeast). These findings build on prior work showing increases in opioid and methamphetamine co-use (regardless of route) among people who inject drugs before the COVID-19 pandemic.



Corresponding Authors: To contact the corresponding authors, email Eshan U. Patel, PhD, MPH, (epatel6@jhmi.edu) and Aaron A. R. Tobian, MD, PhD, (atobian1@jhmi.edu).

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2025.20347)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Embed this link to provide your readers free access to the full-text article 

 https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.20347?guestAccessKey=96e3e8a8-e2b5-40b0-95d7-7ddae33b66e0&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=112625

 

Therapeutic use of cannabis and cannabinoids



JAMA


About The Study: 

Evidence is insufficient for the use of cannabis or cannabinoids for most medical indications. Clear guidance from clinicians is essential to support safe, evidence-based decision-making. Clinicians should weigh benefits against risks when engaging patients in informed discussions about cannabis or cannabinoid use.


Corresponding Author: To contact the corresponding author, Kevin P. Hill, MD, MHS, email khill1@bidmc.harvard.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2025.19433)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Embed this link to provide your readers free access to the full-text article

 https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.19433?guestAccessKey=b7bf42a5-09f4-4c4e-a936-e274698296e1&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=112625